Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...

The winner will be announced Wednesday evening at The American Lawyer's Industry Awards. These attorneys have been named ...

Heritage Pharmaceuticals and Apotex will pay $49.1 million in a settlement with Pennsylvania, New Jersey and other states.

Key targets of the programme are elderly people and children. This programme is a part of Sanofi's commitment to improving ...

(RTTNews) - Shares of GSK plc were losing more than 4 percent on the London Stock Exchange as well as in the early morning trading on the NYSE after the British drug maker reported Wednesday sharply ...

GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. Explore more details here.

This writer thinks GSK shares appear very cheap after the Q3 results, making him wonder if now's the time for him to invest ...

Arguably the biggest development this year is the $2.2bn settlement in the US to end most of its lawsuits in relation to Zantac, the heartburn drug that allegedly caused cancer. This issue has ...

The pharmaceutical giant reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed guidance ...

The latest results were primarily hit by a charge of 1.8 billion pounds or $2.3 billion for the Zantac settlement. On an after- tax basis, the company recorded loss attributable to shareholders of ...